Cardiovascular
Chronic Heart Failure
2
Pipeline Programs↗
4
Active Trials↗
5
Companies Involved↗
Chronic Heart Failure is an early-stage landscape with 2 programs across 5 companies. The most active players are AstraZeneca, Eli Lilly, Vifor Pharma. 1 therapy is approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 21
Phase 3
No programs
Approved1
Analysis
Trial Status
7
clinical trials
Completed3 · 43%
Recruiting3 · 43%
Not yet recruiting1 · 14%
Clinical Trials
Trial Activity
7 trials
Study of the Prevalence of Iron Deficiency Among Hospitalized Patients With HFpEF and the Impact of Ferinject® on Indicators of Quality of Life, Functional Status in Patients With Iron Deficiency
Recruiting·TTomsk National Research Medical Center of the Russian Academy of Sciences·Approved·NCT05793996·100 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)